Quick Dispatch:
Your soul trial oral semaglutide cardiovascular outcomes 2025 SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your soul trial oral semaglutide cardiovascular outcomes 2025 SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with ships.
Need Help?
Questions about soul trial oral semaglutide cardiovascular outcomes 2025 SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for soul trial oral semaglutide cardiovascular outcomes 2025 SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with in your area.
Rethinking the Standard of Care:
25.00
Oral semaglutide found to lower risk of heart failure events in people with type 2 diabetes
23.13
At ADA 2025, the SOUL trial revealed that oral semaglutide (Rybelsus) reduced the risk of major cardiovascular events—like heart attack, stroke, and CV death—by 14% over ~4 years in type 2 diabetes
21.32
Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
24.71
New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral Semaglutide and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis
24.70
Congreso ACC. 25: Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial
28.40
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
29.70
